• Acute Care
    Medicure Focuses On
    Acute Care
    Hospital Products
    Learn More
  • Medicure Investments
    medicure is traded
    on TSX Venture (MPH)
    The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban HCI).
    Presentation
    Investor Information

Aggrastat

Aggrastat® is Medicure's leading speciality pharmaceutical product.

Aggrastat

Investor News

Latest Financial Reports Corporate Presentation

  Latest News

October 3, 2017
Medicure Announces Sale of Apicore Business

August 7, 2017
Medicure Reports Financial Results for Quarter Ended June 30, 2017

July 12, 2017
Medicure Closes Acquisition of Additional Interests in Apicore